Use of MicroRNAs as biomarkers in the early diagnosis of prostate cancer

Main Article Content

Duran Canatan
Ozlem Yılmaz
Yonca Sonmez
Abdullah Cim
Mehmet Baykara
Murat Savas
Hasan Senol Coskun
Sema Sezgin Goksu
Mehmet Rıfkı Aktekin


Prostate cancer, biomarker, microRNA


Introduction: Prostate cancer (PCa) is a common type of cancer in western countries and prominent cause of mortality in men. The aim of the study was to analyze circulating miRNAs as biomarkers in the sera of healthy individuals and prostate cancer cases without biopsy.

Material and methods: Twenty prostate cases, age (mean and range) 61,4±12.1 (45-73), and twenty healthy men, age 59,3±11.2 (44-70) were included to the study. The mean and range of prostate spesific antigen (PSA) in cancer cases and healthy individuals were 6.79±2.84 ng/ml (2.25-14.7) and 3.8±2.2 ng/ml (1.3-7.8) respectively.

Results: Seven miRNAs including two internal controls (Let7c, miR125b, miR141, miR145, miR 155, miR181 ve miR192) were evaluated in two groups. The level of miR141 was significantly lower in PCa cases than healthy individuals (p=0,004), and miR155 was significantly higher (p=0,005) in PCa cases. Both miRNAs were explored sensitive and spesific in the ROC analysis. Tumor mass were found to be associated with the level of miR-125b and miR-145.

Conclusion; validation studies are required in wider patient groups in the subject of tumor effect and miRNA biomarkers in prostate cancer.


Download data is not yet available.
Abstract 103 | PDF Downloads 88


1. Filella X, Fernández-Galan E, Fernández Bonifacio R, Foj L. Emerging biomarkers in the diagnosis of prostate cancer. Pharmgenomics Pers Med. 2018 May 16;11:83-94. doi: 10.2147/PGPM.S136026. eCollection 2018.
2. Moustafa AA, Kim H, Albeltagy RS, MicroRNAs in prostate cancer: From function to biomarker discovery. Exp Biol Med (Maywood). 2018 Jun;243(10):817-825. doi: 10.1177/1535370218775657.
3. Vanacore D, Boccellino M, Rossetti S, Micrornas in prostate cancer: an overview. Oncotarget. 2017 Jul 25;8(30):50240-50251. doi: 10.18632/oncotarget.16933.Epub 2018 Jul 16.
4. Hajian-Tilaki K. Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. Caspian J Intern Med. 2013;4(2):627-35.
5. Porzycki P, Ciszkowicz E, Semik M, Tyrka M. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition. Int Urol Nephrol. 2018 Sep;50(9):1619-1626. doi: 10.1007/s11255-018-1938-2.
6. Shuai Huang, Qingde Wa, Jincheng Pan Downregulation of miR-141-3p Promotes Bone Metastasis via Activating NF-κB Signaling in Prostate Cancer. J Exp Clin Cancer Res, 36 (1), 173, 2017 Dec 4 DOI: 10.1186/s13046-017-0645-7
7. Suh SO, Chen Y, Zaman MS. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis vol.32 no.5 pp.772–778, 2011 doi:10.1093/carcin/bgr036.
8. Richardsen E, Andersen S Melbø-Jørgensen C. et al. MicroRNA 141 Is Associated to Outcome and Aggressive Tumor Characteristics in Prostate Cancer. Sci Rep, 9 (1), 386 2019 Jan 23. DOI: 10.1038/s41598-018-36854-7
9. Guo T, Wang X-X, Fu H Early Diagnostic Role of PSA Combined miR-155 Detection in Prostate Cancer. Eur Rev Med Pharmacol Sci, 22 (6), 1615-1621 Mar 2018 DOI: 10.26355/eurrev_201803_14568
10. Filella X, Foj L. miRNAs as novel biomarkers in the management of prostate cancer. Clin Chem Lab Med. 2017 May 1;55(5):715-736. doi: 10.1515/cclm-2015-1073.
11. Liu Y, Gao S, Du Q, Shao M.J miR-146a and miR-152 in prostate cancer and clinicopathological parameters. BUON. 2019 Jul-Aug;24(4):1692-1699.
12. Zhu C, Hou X, Zhu J, Jiang C, Wei W. Expression of miR-30c and miR-29b in prostate cancer and its diagnostic significance. Oncol Lett. 2018 Sep;16(3):3140-3144. doi: 10.3892/ol.2018.9007. Epub 2018 Jun 21.
13. Greco F, Inferrera A, La Rocca R The Potential Role of MicroRNAs as Biomarkers in Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol Focus. 2018 Feb 2. pii: S2405-4569(18)30009-9. doi: 10.1016/j.euf.2018.01.008. [Epub ahead of print]
14. Al-Kafaji G, Said HM, Alam MA, Al Naieb ZT.Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification. Oncol Lett. 2018 Jul;16(1):1357-1365. doi: 10.3892/ol.2018.8778. Epub 2018 May 22.
15. McDonald AC, Vira M, Shen J Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer. Prostate. 2018 May;78(6):411-418. doi: 10.1002/pros.23485. Epub 2018 Jan 31.
16. Lin Y, Chen F, Shen L Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model. J Transl Med. 2018 May 21;16(1):134. doi: 10.1186/s12967-018-1506-7.
17. Aghdam AM, Amiri A, Salarinia R, MicroRNAs as Diagnostic, Prognostic, and Therapeutic Biomarkers in Prostate Cancer.Crit Rev Eukaryot Gene Expr. 2019;29(2):127-139. doi: 10.1615/CritRevEukaryotGeneExpr.2019025273

Most read articles by the same author(s)

<< < 1 2